Compare Freshworks Inc (FRSH) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Medpace Holdings Inc — how do they compare? Freshworks Inc trades at $13.9 (market cap $3.56B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 4.7× Freshworks Inc's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 9,066,454). Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 39 Days and Medpace Holdings Inc for 14 Days on average.
| FRSH | MEDP | |
|---|---|---|
Market Cap | $3.56B | $16.82B |
Volume | 9,066,454 | 223,093 |
Sector | Technology | Health |
52-Week High | $13.92 | $630.19 |
52-Week Low | $6.88 | $393.42 |
Typical Hold Time | 39 Days | 14 Days |
Enterprise Value | $2.93B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.86, up 1.91% today, reflecting positive momentum following its Q2 2026 earnings beat. The stock exhibits a bullish technical trend with strong moving average signals, though the RSI suggests it may be approaching overbought territory. Fundamentally, the company has achieved a significant turnaround, posting its first GAAP profitable quarter in 2026 with revenue growth of 16% year-over-year, driven by strength in its employee experience portfolio and cost discipline.
The outlook is positive, supported by a 50% analyst buy rating and a consensus price target of $14.60, implying modest upside. Key opportunities include continued AI monetization and market share gains, while risks involve heightened competition in the SaaS sector and the need to sustain recent profitability improvements amid economic uncertainty.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
